• LAST PRICE
    6.2700
  • TODAY'S CHANGE (%)
    Trending Up0.1400 (2.2838%)
  • Bid / Lots
    6.2500/ 8
  • Ask / Lots
    6.2700/ 2
  • Open / Previous Close
    6.2900 / 6.1300
  • Day Range
    Low 6.2200
    High 6.4800
  • 52 Week Range
    Low 2.5700
    High 6.8800
  • Volume
    119,223
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 6.13
TimeVolumeCNCE
09:32 ET135796.4113
09:34 ET50346.435
09:36 ET35536.375
09:38 ET44096.4345
09:39 ET131086.395
09:41 ET55666.38
09:43 ET120666.38
09:45 ET39696.345
09:48 ET62426.31
09:50 ET9966.31
09:52 ET38046.33
09:54 ET50506.3285
09:56 ET46726.2774
09:57 ET67656.305
09:59 ET4506.305
10:01 ET6006.3
10:03 ET25016.26
10:06 ET1006.24
10:08 ET24736.24
10:10 ET10906.25
10:14 ET3006.25
10:15 ET9416.29
10:17 ET40356.27
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCNCE
Concert Pharmaceuticals Inc
284.8M
-2.4x
---
United StatesPSTX
Poseida Therapeutics Inc
257.8M
-1.7x
---
United StatesVYGR
Voyager Therapeutics Inc
266.5M
-3.5x
---
United StatesEPZM
Epizyme Inc
255.9M
-0.7x
---
United StatesALPN
Alpine Immune Sciences Inc
269.9M
-5.1x
---
United StatesAVEO
Aveo Pharmaceuticals Inc
268.2M
-6.7x
---
As of 2022-08-08

Company Information

Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Contact Information

Headquarters
Suite 500, 99 Hayden AvenueLEXINGTON, MA, United States 02421
Phone
781-860-0045
Fax
302-636-5454

Executives

Independent Chairman of the Board, Co-founder
Richard Aldrich
President, Chief Executive Officer, Co-Founder, Director
Roger Tung
Chief Financial Officer
Marc Becker
Chief Operating Officer
Nancy Stuart
Chief Development Officer
James Cassella

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$284.8M
Revenue (TTM)
$32.6M
Shares Outstanding
46.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.68
EPS
$-2.67
Book Value
$3.23
P/E Ratio
-2.4x
Price/Sales (TTM)
8.7
Price/Cash Flow (TTM)
---
Operating Margin
-274.94%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.